BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.

Other research analysts have also recently issued research reports about the company. Ascendiant Capital Markets cut their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Stock Up 1.4 %

Shares of BIOLASE stock opened at $0.01 on Friday. The firm has a market cap of $250,552.50, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94. The company’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.05.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.